Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

Tsutomu Takeuchi, Y. Tatsuki, Y. Nogami, N. Ishiguro, Y. Tanaka, H. Yamanaka, N. Kamatani, M. Harigai, J. Ryu, K. Inoue, H. Kondo, S. Inokuma, T. Ochi, T. Koike

Research output: Contribution to journalArticle

253 Citations (Scopus)

Abstract

Objectives: A large-scale postmarketing surveillance (PMS) study was carried out to determine the safety profile of infliximab in Japanese patients with rheumatoid arthritis (RA). Methods: The PMS study was performed for all patients with RA who were treated with infliximab. They were consecutively registered in the PMS study at the initiation of infliximab treatment and were prospectively monitored with all adverse events noted for a period of 6 months. All case reports, which include safety-related events, were collected monthly. Results: Adverse drug reactions (ADRs) were assessed for 6 months in 5000 patients who were consecutively enrolled in the PMS study. The incidence rates of total and serious ADRs were 28.0% and 6.2%, respectively. "Infections" or "respiratory disorders" were most commonly observed among serious ADRs. Bacterial pneumonia developed in 2.2%, tuberculosis in 0.3%, suspected Pneumocystis jiroveci pneumonia (PCP) in 0.4% and interstitial pneumonitis in 0.5%. Bacterial pneumonia (for which individuals of male gender, of older age and those with advanced rheumatoid arthritis and comorbid respiratory disease were most at risk) began to develop immediately after the start of treatment, while tuberculosis, PCP and interstitial pneumonitis developed about 1 month later. Serious infusion reactions were observed in 0.5% and were more likely to occur in patients who had participated in previous clinical trials of infliximab. Conclusion: This postmarketing surveillance study of patients treated with infliximab showed that infliximab in combination with low-dose MTX was well tolerated in Japanese patients with active RA.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume67
Issue number2
DOIs
Publication statusPublished - 2008 Feb
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Safety
Drug-Related Side Effects and Adverse Reactions
Bacterial Pneumonia
Pneumocystis carinii
Pneumocystis Pneumonia
Interstitial Lung Diseases
Tuberculosis
Pharmaceutical Preparations
Pulmonary diseases
Respiratory Tract Infections
Infliximab
Clinical Trials
Incidence
Therapeutics

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. / Takeuchi, Tsutomu; Tatsuki, Y.; Nogami, Y.; Ishiguro, N.; Tanaka, Y.; Yamanaka, H.; Kamatani, N.; Harigai, M.; Ryu, J.; Inoue, K.; Kondo, H.; Inokuma, S.; Ochi, T.; Koike, T.

In: Annals of the Rheumatic Diseases, Vol. 67, No. 2, 02.2008, p. 189-194.

Research output: Contribution to journalArticle

Takeuchi, T, Tatsuki, Y, Nogami, Y, Ishiguro, N, Tanaka, Y, Yamanaka, H, Kamatani, N, Harigai, M, Ryu, J, Inoue, K, Kondo, H, Inokuma, S, Ochi, T & Koike, T 2008, 'Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis', Annals of the Rheumatic Diseases, vol. 67, no. 2, pp. 189-194. https://doi.org/10.1136/ard.2007.072967
Takeuchi, Tsutomu ; Tatsuki, Y. ; Nogami, Y. ; Ishiguro, N. ; Tanaka, Y. ; Yamanaka, H. ; Kamatani, N. ; Harigai, M. ; Ryu, J. ; Inoue, K. ; Kondo, H. ; Inokuma, S. ; Ochi, T. ; Koike, T. / Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. In: Annals of the Rheumatic Diseases. 2008 ; Vol. 67, No. 2. pp. 189-194.
@article{0d08b8bed695488088de03dfbdf742e9,
title = "Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis",
abstract = "Objectives: A large-scale postmarketing surveillance (PMS) study was carried out to determine the safety profile of infliximab in Japanese patients with rheumatoid arthritis (RA). Methods: The PMS study was performed for all patients with RA who were treated with infliximab. They were consecutively registered in the PMS study at the initiation of infliximab treatment and were prospectively monitored with all adverse events noted for a period of 6 months. All case reports, which include safety-related events, were collected monthly. Results: Adverse drug reactions (ADRs) were assessed for 6 months in 5000 patients who were consecutively enrolled in the PMS study. The incidence rates of total and serious ADRs were 28.0{\%} and 6.2{\%}, respectively. {"}Infections{"} or {"}respiratory disorders{"} were most commonly observed among serious ADRs. Bacterial pneumonia developed in 2.2{\%}, tuberculosis in 0.3{\%}, suspected Pneumocystis jiroveci pneumonia (PCP) in 0.4{\%} and interstitial pneumonitis in 0.5{\%}. Bacterial pneumonia (for which individuals of male gender, of older age and those with advanced rheumatoid arthritis and comorbid respiratory disease were most at risk) began to develop immediately after the start of treatment, while tuberculosis, PCP and interstitial pneumonitis developed about 1 month later. Serious infusion reactions were observed in 0.5{\%} and were more likely to occur in patients who had participated in previous clinical trials of infliximab. Conclusion: This postmarketing surveillance study of patients treated with infliximab showed that infliximab in combination with low-dose MTX was well tolerated in Japanese patients with active RA.",
author = "Tsutomu Takeuchi and Y. Tatsuki and Y. Nogami and N. Ishiguro and Y. Tanaka and H. Yamanaka and N. Kamatani and M. Harigai and J. Ryu and K. Inoue and H. Kondo and S. Inokuma and T. Ochi and T. Koike",
year = "2008",
month = "2",
doi = "10.1136/ard.2007.072967",
language = "English",
volume = "67",
pages = "189--194",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

AU - Takeuchi, Tsutomu

AU - Tatsuki, Y.

AU - Nogami, Y.

AU - Ishiguro, N.

AU - Tanaka, Y.

AU - Yamanaka, H.

AU - Kamatani, N.

AU - Harigai, M.

AU - Ryu, J.

AU - Inoue, K.

AU - Kondo, H.

AU - Inokuma, S.

AU - Ochi, T.

AU - Koike, T.

PY - 2008/2

Y1 - 2008/2

N2 - Objectives: A large-scale postmarketing surveillance (PMS) study was carried out to determine the safety profile of infliximab in Japanese patients with rheumatoid arthritis (RA). Methods: The PMS study was performed for all patients with RA who were treated with infliximab. They were consecutively registered in the PMS study at the initiation of infliximab treatment and were prospectively monitored with all adverse events noted for a period of 6 months. All case reports, which include safety-related events, were collected monthly. Results: Adverse drug reactions (ADRs) were assessed for 6 months in 5000 patients who were consecutively enrolled in the PMS study. The incidence rates of total and serious ADRs were 28.0% and 6.2%, respectively. "Infections" or "respiratory disorders" were most commonly observed among serious ADRs. Bacterial pneumonia developed in 2.2%, tuberculosis in 0.3%, suspected Pneumocystis jiroveci pneumonia (PCP) in 0.4% and interstitial pneumonitis in 0.5%. Bacterial pneumonia (for which individuals of male gender, of older age and those with advanced rheumatoid arthritis and comorbid respiratory disease were most at risk) began to develop immediately after the start of treatment, while tuberculosis, PCP and interstitial pneumonitis developed about 1 month later. Serious infusion reactions were observed in 0.5% and were more likely to occur in patients who had participated in previous clinical trials of infliximab. Conclusion: This postmarketing surveillance study of patients treated with infliximab showed that infliximab in combination with low-dose MTX was well tolerated in Japanese patients with active RA.

AB - Objectives: A large-scale postmarketing surveillance (PMS) study was carried out to determine the safety profile of infliximab in Japanese patients with rheumatoid arthritis (RA). Methods: The PMS study was performed for all patients with RA who were treated with infliximab. They were consecutively registered in the PMS study at the initiation of infliximab treatment and were prospectively monitored with all adverse events noted for a period of 6 months. All case reports, which include safety-related events, were collected monthly. Results: Adverse drug reactions (ADRs) were assessed for 6 months in 5000 patients who were consecutively enrolled in the PMS study. The incidence rates of total and serious ADRs were 28.0% and 6.2%, respectively. "Infections" or "respiratory disorders" were most commonly observed among serious ADRs. Bacterial pneumonia developed in 2.2%, tuberculosis in 0.3%, suspected Pneumocystis jiroveci pneumonia (PCP) in 0.4% and interstitial pneumonitis in 0.5%. Bacterial pneumonia (for which individuals of male gender, of older age and those with advanced rheumatoid arthritis and comorbid respiratory disease were most at risk) began to develop immediately after the start of treatment, while tuberculosis, PCP and interstitial pneumonitis developed about 1 month later. Serious infusion reactions were observed in 0.5% and were more likely to occur in patients who had participated in previous clinical trials of infliximab. Conclusion: This postmarketing surveillance study of patients treated with infliximab showed that infliximab in combination with low-dose MTX was well tolerated in Japanese patients with active RA.

UR - http://www.scopus.com/inward/record.url?scp=38749119069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749119069&partnerID=8YFLogxK

U2 - 10.1136/ard.2007.072967

DO - 10.1136/ard.2007.072967

M3 - Article

VL - 67

SP - 189

EP - 194

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 2

ER -